Clindamycin phosphate vaginal cream

In a one-year retrospective study at a tertiary hospital in Spain, 17% of 148 episodes of diarrhea associated with C. difficile developed after therapy with clindamycin (26). The possible association of toxin-positive C. difficile-induced colitis and the use of clindamycin phosphate vaginal cream for bacterial vaginosis has been reported in a 25-year-old white woman postpartum (27). 

Meadoweroft AM, Diaz PR, Latham GS. Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. Ann Pharmacother 1998 32(3) 309-11. 

Levinson, R. S., Mitan, S. J., Steinmetz, J. I., Gattermeir, D. J., Schumacher, R. J., and Joffrion, J. L. (2005), An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations, Clin. Ther., 27,1894-1900. 

Whereas only about 4% of clindamycin from a vaginal cream was systemically absorbed, systemic absorption was in the range of 30% when clindamycin was intra-vaginally administered as a phosphate ovule (67). 

Clindamycin phosphate is a water-soluble ester of the semisynthetic antibiotic produced by a 7(S)-chloro- substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(l-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1 -thio-L-threo-(alpha)-D-galacto-octopyranoside 2-(dihydrogen phosphate). It has a molecular weight of 504.96, and the molecular formula is C 8HhCIN208. Vaginal cream, 2%,... 

---